MENU

08.06.20

Ofatumumab Reduced Annualized Relapse Rate in MS in Phase 3 Clinical Trials 

  • KEYWORDS:
  • Multiple sclerosis
  • Ofatumumab
  • Relapsing Multiple Sclerosis

As published in The New England Journal of Medicine (NEJM), the ASCLEPIOS 1 (NCT02792218) and 2 (NCT02792231) studies of ofatumumab (OMB157) show a significant reduction in annualized relapse rate (ARR), gadolinium enhancing (Gd+) T1 lesions, and neuroaxonal damage.

The studies compared treatment with ofatumumab (20 mg/month subcutaneously ) vs teriflunomide (14 mg/day orally) in adults with relapsing forms of multiple sclerosis (MS). Results from the ASCLEPIOS 1 and 2 studies showed that compared with teriflunomide, ofatumumab: 

•    Significantly reduced the ARR by 51% (0.11 vs 0.22) and 58% (0.10 vs 0.25) in ASCLEPIOS 1 and 2 (P<.001 in both studies)
•    Was associated with a relative risk reduction of 34% (P=.002) in 3-month confirmed disability worsening (CDW) and 32% (P=.01) in 6-month CDW 
•    Significantly reduced both gadolinium enhancing (Gd+) T1 lesions (97% and 94% relative reduction in ASCLEPIOS 1 and 2, respectively;  P<.001), and  new or enlarging T2 lesions ( 82% and 85% relative reduction, respectively; P<.001).
•    higher reductions of neurofilament light chain (NfL) serum concentrations suggesting  prevention of axonal damage ,a major determinant of irreversible neurologic disability in MS 
•    Injection-related reactions, including nasopharyngitis, headache, injection-site reaction, upper respiratory tract infection and urinary tract infection were the most commonly observed adverse events with ofatumumab, occurring in ≥10% of participants.

The ASCLEPIOS 1 and 2 studies are twin, identical design flexible duration (up to 30 months) double-blind  randomized, multicenter phase 3 studies evaluating the safety and efficacy of ofatumumab (20 mg/month subcutaneously) injections vs teriflunomide (14 mg/day orally). The ASCLEPIOS 1 and 2 studies enrolled 1,882 participants with MS, between the ages of 18 and 55 years who had expanded disability status scale (EDSS) scores between 0 and 5.5.
 

Clinical Trials Begin for Combination of Interferon Beta-1A and Remdesivir

Previous News Article

Mortality of Unruptured Brain Aneurysms Reduced By Advances in Treatment 

Next News Article
This Month's Issue
Trending Autoantibodies Causing Movement Disorders

F. Stephen Benesh, MD, and Shruti P. Agnihotri, MD

Utility of Autoantibody Profiles

Shailee S. Shah, MD, and Andrew McKeon, MD